Free tool
FAERS Monitor: Cabometyx
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208692 or its brand name (Cabometyx, Cabozantinib S-Malate). Reports on generic versions are filed under their own applications.
Reports
45,867
Serious
20,559
45% of reports
Hospitalization
8,827
Death reported
5,123
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea8,923
- fatigue7,330
- off label use6,092
- nausea4,724
- decreased appetite4,414
- malignant neoplasm progression3,284
- blood pressure increased3,107
- palmar-plantar erythrodysaesthesia syndrome3,042
- weight decreased2,872
- death2,797
- stomatitis2,731
- constipation2,284
- vomiting2,093
- asthenia2,006
- taste disorder1,989
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 16 |
| 2014 | 107 |
| 2015 | 87 |
| 2016 | 159 |
| 2017 | 1,452 |
| 2018 | 3,369 |
| 2019 | 3,853 |
| 2020 | 2,940 |
| 2021 | 4,546 |
| 2022 | 5,885 |
| 2023 | 6,053 |
| 2024 | 6,461 |
| 2025 | 6,037 |
| 2026 | 4,898 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,008,292 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| palmar-plantar erythrodysaesthesia syndromeSignal | 3,042 | 68.7 | 66.2 | 176,512 |
| taste disorderSignal | 1,989 | 49.7 | 47.5 | 85,713 |
| stomatitisSignal | 2,731 | 21.6 | 20.8 | 51,300 |
| malignant neoplasm progressionSignal | 3,284 | 15.2 | 14.7 | 42,230 |
| blood pressure increasedSignal | 3,107 | 9.5 | 9.2 | 23,285 |
| decreased appetiteSignal | 4,414 | 8.9 | 8.6 | 30,540 |
| diarrhoeaSignal | 8,923 | 6.4 | 6.3 | 41,479 |
| constipationSignal | 2,284 | 4.8 | 4.7 | 6,960 |
| weight decreasedSignal | 2,872 | 4.8 | 4.6 | 8,542 |
| fatigueSignal | 7,330 | 4.3 | 4.3 | 19,441 |
| off label useSignal | 6,092 | 3.2 | 3.1 | 9,578 |
| nauseaSignal | 4,724 | 2.7 | 2.7 | 5,421 |
| astheniaSignal | 2,006 | 2.5 | 2.4 | 1,749 |
| vomitingSignal | 2,093 | 2.0 | 2.0 | 1,139 |
| death | 2,797 | 1.5 | 1.4 | 468 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.